New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease
Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news
More News: Chronic Kidney Disease | Dapagliflozin | Forxiga | Germany Health | Health | Spain Health | Study | Urology & Nephrology